Vanguard Group Inc Biomarin Pharmaceutical Inc Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
A detailed history of Vanguard Group Inc transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Vanguard Group Inc holds 18,117,108 shares of BMRN stock, worth $1.49 Billion. This represents 0.03% of its overall portfolio holdings.
Number of Shares
18,117,108
Previous 18,050,062
0.37%
Holding current value
$1.49 Billion
Previous $1.74 Billion
9.08%
% of portfolio
0.03%
Previous 0.04%
Shares
13 transactions
Others Institutions Holding BMRN
# of Institutions
623Shares Held
181MCall Options Held
1.73MPut Options Held
1.73M-
Primecap Management CO Pasadena, CA18.7MShares$1.54 Billion1.24% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$1.19 Billion0.03% of portfolio
-
Dodge & Cox San Francisco, CA14MShares$1.15 Billion0.75% of portfolio
-
State Street Corp Boston, MA6.9MShares$568 Million0.03% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.52MShares$537 Million0.13% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $15.3B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...